Anacor Pharmaceuticals, Inc. (ANAC) Posts Q4 Loss of 52c/Share

Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) reported Q4 EPS of ($0.52), $0.17 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $6.64 million.

For earnings history and earnings-related data on Anacor Pharmaceuticals, Inc. (ANAC) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Rexford Industrial agrees to sell $1.2B portfolio to EQT Real Estate
• Home Depot beats estimates, reaffirms fiscal 2026 guidance